NAT2 and urinary bladder cancer: The observed net protective effect of the SNP-inferred NAT2 slow acetylation status on bladder cancer risk may reflect both the high prevalence of NAT2 rapid acetylation status and exposure to bladder carcinogens that are uniquely catalyzed through the O-acetylation activation pathway in the study population.